Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Revive Therapeutics Ltd. (V.RVV) had Consolidated Net Income/Loss of -4.75M for the most recently reported fiscal quarter, ending 2022-03-31.
| Income Statement Financials | |
-- |
|
-4.75M |
|
-- |
|
-- |
|
-- |
|
-4.75M |
|
-- |
|
-4.75M |
|
-4.75M |
|
-4.75M |
|
-4.75M |
|
|
Consolidated Net Income/Loss |
-4.75M |
-4.75M |
|
-4.75M |
|
-4.75M |
|
320.11M |
|
320.11M |
|
-0.02 |
|
-0.02 |
|
| Balance Sheet Financials | |
-- |
|
-- |
|
-- |
|
14.55M |
|
-- |
|
-- |
|
-- |
|
2.63M |
|
11.92M |
|
2.05M |
|
11.92M |
|
320.68M |
|
| Cash Flow Statement Financials | |
-9.10M |
|
-- |
|
0.16M |
|
13.10M |
|
4.17M |
|
-8.93M |
|
0.82M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.83 |
|
-- |
|
-- |
|
0.02 |
|
0.02 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-9.10M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-39.88% |
|
-231.56% |
|
-32.67% |
|
-39.24% |
|
0.05 |
|
-0.03 |
|
-0.03 |
|